Exenatide

When taking GLP-1 receptor agonists, adults with type 2 diabetes may achieve larger decreases in HbA1c with either dulaglutide or exenatide treatment compared with liraglutide, although dulaglutide could provide more benefit than both medications, according to findings published in Metabolism.

Adolescents with obesity assigned the weekly GLP-1 receptor agonist exenatide for 6 months experienced a modest reduction in BMI along with improvements in several cardiometabolic markers, including 2-hour glucose and lipid profile, according to findings published in Pediatric Obesity.

Among a cohort of Japanese adults with type 2 diabetes, HbA1c and fasting plasma glucose fell and beta-cell function rose after a change from exenatide twice per day to exenatide once per week, according to findings published in the Journal of Diabetes Investigation.

CHICAGO — GLP-1 receptor agonists are a medication class that has exhibited many benefits, especially in the cardiovascular realm, since being introduced, and more recent evidence has only solidified this notion, but the mechanisms behind their success are still difficult to pin down, according to a speaker at the Cardiometabolic Health Congress.

PHILADELPHIA — Among patients with type 2 diabetes and confirmed CVD at baseline, treatment with once-weekly exenatide reduced the risk for major adverse CV events, with no new or overall safety concerns related to cardiac events, according to a prespecified subgroup analysis of the EXSCEL study.